Seeking Alpha
25 Oct 2026, 08:34 UTC · 2h ago
Ocular Therapeutix: The Drug Won, The Stock Lost, And That's The Opportunity
Impact · against what's priced in
The article presents a bullish case for OCUL based on strong Phase 3 data and an upcoming NDA filing, but it acknowledges that the market has already priced in significant peak sales of $1.26 billion. Consequently, the catalyst for upside is not the drug's efficacy—which is established—but rather future execution and potential upward revisions to sales estimates.
- OCUL+0.20
No priced-in read yet
- In context
The expectation to file the NDA in Q4 2026 for a 2027 launch transforms the company from clinical-stage burn to revenue generation, though the market already factors in $1.26 billion in peak U.S. sales.
Read from the article alone
